Tyrogenex Inc. to Present at BIO National Venture Conference 2009

WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Tyrogenex Inc., a company focused on an oral, multi-kinase angiogenesis inhibitor, is pleased to announce that Sheridan G. Snyder, President and Chief Executive Officer, will present at BIO National Venture Conference on Tuesday, March 31, 2009 at 2:20 PM in Boston, Massachusetts.

Mr. Snyder will provide an overview of Tyrogenex and its lead candidate, X-82, an oral, VEGFR/PDGFR inhibitor currently in development for solid tumors.

About Tyrogenex Inc.

Tyrogenex Inc. is a biotechnology company, headquartered in West Palm Beach, Florida, USA, focused on the research and development of its multi-kinase angiogenesis inhibitor for the treatment of solid tumors. Tyrogenex’s lead candidate, X-82, is finalizing preclinical studies and preparing to enter Phase I clinical trials. For more information about Tyrogenex, please visit www.tyrogenex.com.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, plan and future development of Tyrogenex Inc.’s products and technologies. These forward-looking statements about future expectations, plans and prospects of the development of Tyrogenex Inc.’s products and technologies involve significant risks, uncertainties and assumptions, including the risk that the development of our multi-kinase inhibitor may be delayed or may not proceed as planned and we may not be able to complete development of any multi-kinase-based product, the risk that the FDA approval process may be delayed for any drugs that we develop, risks related to development and commercialization of products by our competitors, risks related to our ability to control the timing and terms of collaborations with third parties and the possibility that other companies or organizations may assert patent rights that prevent us from developing our products. Actual results may differ materially from those Tyrogenex Inc. contemplated by these forward-looking statements. Tyrogenex Inc. does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.